Almujtama Alraida Medical (9592) Fundamentals 2026 — P/E 26.0x, Revenue Analysis | SniperIQ
Almujtama Alraida Medical (9592) is a SA-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of SAR 217M, trading at SAR 22.89 on the SAU. This SniperIQ fundamentals page covers Almujtama Alraida Medical's valuation (P/E 26.0x, P/B 1.5x), profitability (net margin 1.8%), revenue (SAR 455M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Almujtama Alraida Medical's market cap?
Almujtama Alraida Medical (9592) has a market capitalization of approximately SAR 217M, trading at SAR 22.89 on the SAU. Market cap moves with the live share price.
What is Almujtama Alraida Medical's P/E ratio?
Almujtama Alraida Medical's trailing twelve-month P/E ratio is 26.0x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Almujtama Alraida Medical?
Almujtama Alraida Medical runs a net profit margin of 1.8%, a gross margin of 32.9%, and an operating margin of 32.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Almujtama Alraida Medical generate?
Almujtama Alraida Medical reported revenue of SAR 455M for fiscal year 2025, with net income of SAR 8M and earnings per share (EPS) of 0.88. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Almujtama Alraida Medical pay a dividend?
Almujtama Alraida Medical offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Almujtama Alraida Medical financially healthy?
Almujtama Alraida Medical carries a debt-to-equity ratio of 1.35x and a current ratio of 1.07x, with a market beta of 0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Almujtama Alraida Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Almujtama Alraida Medical (9592) the key facts are: market cap SAR 217M, P/E 26.0x, revenue SAR 455M, 52-week range 21.5-33.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Almujtama Alraida Medical's full fundamentals live
Get Almujtama Alraida Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.